Funded Biotechnology Startups in Irvine
Irvine's biotechnology sector spans the full capital stack, from NXT Biomedical's $250K Seed round in August 2022 to Tarsus Pharmaceuticals' $125M close in…
Irvine's biotechnology sector spans the full capital stack, from NXT Biomedical's $250K Seed round in August 2022 to Tarsus Pharmaceuticals' $125M close in March 2025. The 15 rounds shown here date from December 2020 through March 2025, with meaningful activity in every year across that window. The two largest disclosed amounts — $125M each to Tarsus Pharmaceuticals and Evolus (Post-IPO Debt, December 2021) — are nearly matched by CG Oncology's $120M Series E in November 2022.
Eight of the 15 rounds carry a Series Unknown classification, including MDxHealth's $40M raise in September 2024 and Immunis's $16M in July 2024, indicating non-standard or undisclosed structures are common in this segment. Oncology represents a recurring focus — CG Oncology, OncoCyte, and AiVita Biomedical all appear. Stage diversity is broad: Hancock Jaffe Laboratories and Evolus both completed post-IPO raises, while Matregenix received a grant in September 2022 and Biosynthetic Technologies closed a Series A of $8M in February 2022.
Most recent rounds
15 shownRelated listings
Frequently asked
What are the largest disclosed rounds in this dataset?
The three largest are $125M to Tarsus Pharmaceuticals (March 2025, Series Unknown), $125M in Post-IPO Debt to Evolus (December 2021), and $120M in a Series E to CG Oncology (November 2022). All three exceed the $40M MDxHealth raised in September 2024, which is the next largest.
Which round types appear across these Irvine biotech companies?
Eight of the 15 rounds carry a Series Unknown classification. The remainder span Seed (NXT Biomedical, $250K), Series A (Biosynthetic Technologies, $8M), Series E (CG Oncology, $120M), Post-IPO Debt (Evolus, $125M), Post-IPO Equity (Hancock Jaffe Laboratories, $20M), and a grant with undisclosed amount (Matregenix).
Are any of these companies raising capital after going public?
Two companies in the dataset have completed post-IPO rounds: Evolus raised $125M in Post-IPO Debt in December 2021, and Hancock Jaffe Laboratories raised $20M in Post-IPO Equity in September 2021.
Is there a dominant sub-sector among Irvine biotech fundings shown here?
Oncology is the most visible theme. CG Oncology, OncoCyte, and AiVita Biomedical all focus on cancer-related applications, and together they account for three of the 15 companies listed.
How recent is the most recent funding event, and how far back does the data go?
The most recent round is Tarsus Pharmaceuticals' $125M close on March 12, 2025. The earliest in the dataset is AiVita Biomedical's $25M raise on December 29, 2020, giving the list a roughly four-year span.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.